Market Overview:
The global high purity heparin market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing demand for heparin sodium and other types of high purity heparins from various applications, such as unfractionated heparin and low molecular weight heparins (LMWHs). North America is expected to lead the global high purity heparn market during the forecast period, followed by Europe. Asia Pacific is projected to be the fastest-growing region in this market during the forecast period.
Product Definition:
High purity heparin is a form of the anticoagulant drug heparin that has been purified to remove impurities. High purity heparin is used in medical procedures to prevent blood clots from forming.
Heparin Sodium:
Heparin sodium is a low molecular weight heparin used as an anticoagulant and thrombolytic agent. It is commonly known by the brand name “Urokinase”. Heparin sodium finds application in various medical fields such as angina pectoris treatment, acute coronary syndrome (ACS) treatment, renal dialysis, and prevention of Deep Vein Thrombosis (DVT).
Heparin Calcium:
Heparin calcium is a form of high purity heparin used to treat deep vein thrombosis, pulmonary embolism, and heart attack. It works by lowering the blood clotting tendency. The drug was developed in the early 1960s and it has been undergoing various modifications since then. Currently, it is sold with an FDA approved prescription for internal use only as there are no commercial products for external use at present time.
Application Insights:
Based on the application, the global market is segmented into cardiovascular diseases, renal impairment and others. Cardiovascular diseases held a major share in 2017 owing to high prevalence of target population globally. Moreover, growing awareness about risk factors associated with CVDs such as smoking and obesity is expected to drive demand for heparin globally over the forecast period.
Renal impairment segment is anticipated to witness significant growth over the forecast period due to rising incidence of chronic kidney disease (CKD). According to estimates reported by National Chronic Kidney Disease Fact Sheet published by CDC in 2018, nearly 30 million people have CKD worldwide which was estimated around 2015 that includes CKD stage 1 & 2 patients. Hemorrhagic stroke accounted for largest share in terms of revenue among other applications globally as heparin has been proved effective against cerebral hemorrhage thus providing relief from stroke-related symptoms such as headache and neck stiffness.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to maintain its dominance over the forecast period owing to rising healthcare expenditure and increasing prevalence of cardiovascular diseases and hypertension. In addition, growing awareness regarding blood clotting disorders is anticipated to propel product demand in North America during the forecast period.
Asia Pacific is expected to witness lucrative growth over the coming years owing to rising healthcare expenditure by governments as well as individuals, improving infrastructure for medical treatment, increase in geriatric population prone towards chronic diseases such as stroke and heart failure along with an increase in blood coagulation disorders such as Deep Vein Thrombosis (DVT) & Pulmonary Embolism (PE). These factors are likely drive regional market growth during the estimated time span.
Growth Factors:
- Increasing demand for heparin in the treatment of thrombosis and other medical conditions
- Growing number of surgical procedures requiring use of heparin
- Rising incidence of venous thromboembolism (VTE) and deep vein thrombosis (DVT)
- Technological advancements in the production of high purity heparin 5. Increasing awareness about the benefits of using high purity heparin
Scope Of The Report
Report Attributes
Report Details
Report Title
High Purity Heparin Market Research Report
By Type
Heparin Sodium, Heparin Calcium, Other
By Application
Unfractionated Heparin, Low Molecular Heparin
By Companies
Hepalink, Changshan Pharm, Qianhong Bio-pharma, Opocrin, Pfizer, Aspen Oss, King-friend Biochemical Pharmaceutical, Bioibérica, Dongcheng Biochemicals, Jiulong Biochemicals, Tiandong, Xinbai, Yino Pharma Limited, Deebio
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
120
Number of Tables & Figures
84
Customization Available
Yes, the report can be customized as per your need.
Global High Purity Heparin Market Report Segments:
The global High Purity Heparin market is segmented on the basis of:
Types
Heparin Sodium, Heparin Calcium, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Unfractionated Heparin, Low Molecular Heparin
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Hepalink
- Changshan Pharm
- Qianhong Bio-pharma
- Opocrin
- Pfizer
- Aspen Oss
- King-friend Biochemical Pharmaceutical
- Bioibérica
- Dongcheng Biochemicals
- Jiulong Biochemicals
- Tiandong
- Xinbai
- Yino Pharma Limited
- Deebio
Highlights of The High Purity Heparin Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Heparin Sodium
- Heparin Calcium
- Other
- By Application:
- Unfractionated Heparin
- Low Molecular Heparin
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the High Purity Heparin Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
High Purity Heparin is a type of heparin that has been purified to the highest degree possible. This means that it has been removed from other substances, such as antibodies or other proteins, which could potentially cause side effects.
Some of the key players operating in the high purity heparin market are Hepalink, Changshan Pharm, Qianhong Bio-pharma, Opocrin, Pfizer, Aspen Oss, King-friend Biochemical Pharmaceutical, Bioib©rica, Dongcheng Biochemicals, Jiulong Biochemicals, Tiandong, Xinbai, Yino Pharma Limited, Deebio.
The high purity heparin market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 High Purity Heparin Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 High Purity Heparin Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 High Purity Heparin Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the High Purity Heparin Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global High Purity Heparin Market Size & Forecast, 2020-2028 4.5.1 High Purity Heparin Market Size and Y-o-Y Growth 4.5.2 High Purity Heparin Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Heparin Sodium
5.2.2 Heparin Calcium
5.2.3 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Unfractionated Heparin
6.2.2 Low Molecular Heparin
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global High Purity Heparin Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 High Purity Heparin Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Heparin Sodium
9.6.2 Heparin Calcium
9.6.3 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Unfractionated Heparin
9.10.2 Low Molecular Heparin
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Heparin Sodium
10.6.2 Heparin Calcium
10.6.3 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Unfractionated Heparin
10.10.2 Low Molecular Heparin
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Heparin Sodium
11.6.2 Heparin Calcium
11.6.3 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Unfractionated Heparin
11.10.2 Low Molecular Heparin
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Heparin Sodium
12.6.2 Heparin Calcium
12.6.3 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Unfractionated Heparin
12.10.2 Low Molecular Heparin
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Heparin Sodium
13.6.2 Heparin Calcium
13.6.3 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Unfractionated Heparin
13.10.2 Low Molecular Heparin
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 High Purity Heparin Market: Competitive Dashboard
14.2 Global High Purity Heparin Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Hepalink
14.3.2 Changshan Pharm
14.3.3 Qianhong Bio-pharma
14.3.4 Opocrin
14.3.5 Pfizer
14.3.6 Aspen Oss
14.3.7 King-friend Biochemical Pharmaceutical
14.3.8 Bioibérica
14.3.9 Dongcheng Biochemicals
14.3.10 Jiulong Biochemicals
14.3.11 Tiandong
14.3.12 Xinbai
14.3.13 Yino Pharma Limited
14.3.14 Deebio